Physician profile
Benjamin L Walter
NPI 1184689093
$209,805.63
in general payments reported to CMS, 2019-2025
17 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $17K · 2021: $17K · 2022: $33K · 2023: $37K · 2024: $41K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $22K · Travel and Lodging: $19K · Food and Beverage: $8,849 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,750 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,525.75 |
| Consulting Fee | $21,760.00 |
| Travel and Lodging | $18,603.21 |
| Food and Beverage | $8,849.01 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,750.00 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58,284.85 | 2020-2025 | Infinity, Proclaim |
| Teva Pharmaceuticals USA, INC. | $52,437.49 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Medtronic, INC. | $21,919.25 | 2021-2025 | Percept PC Brainsense, Activa PC |
| Boston Scientific Corporation | $20,573.32 | 2019-2025 | Vercise, General - Dbs |
| Medtronic USA, INC. | $11,398.21 | 2019-2020 | |
| Mdd US Operations, LLC | $10,830.59 | 2024-2025 | Apokyn |
| Lundbeck LLC | $10,618.74 | 2019-2020 | |
| Acorda Therapeutics, INC | $7,576.08 | 2019-2023 | Inbrija |
| Tanabe Pharma America, INC. | $7,231.81 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $4,908.93 | 2019-2025 | Crexont, Rytary |
| Abbvie INC. | $2,820.78 | 2020-2025 | Botox |
| Neurocrine Biosciences, INC. | $456.14 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $359.27 | 2019-2024 | Nuplazid |
| Insightec,INC | $197.80 | 2025 | Exablate |
| Merz Pharmaceuticals, LLC | $105.86 | 2024 | Xeomin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $67.41 | 2023 | Dhivy |
| Actelion Pharmaceuticals US, INC. | $19.10 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.